Pheresthal (Tablets) Instructions for Use
Marketing Authorization Holder
Bryntsalov-A, JSC (Russia)
ATC Code
A09AA02 (Polyenzyme preparations (incl. lipase, protease))
Active Substances
Pancreatin (BAN)
Hemicellulase (Group)
Bile (Group)
Dosage Form
| Pheresthal | Enteric-coated tablets: 10, 20, 30, 50, 60, 80, or 100 pcs. |
Dosage Form, Packaging, and Composition
| Enteric-coated tablets | 1 tablet |
| Pancreatin | 192-210 mg |
| Hemicellulase | 50 mg |
| Ox bile extract | 25 mg |
10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
50 pcs. – plastic containers (1) – cardboard packs.
60 pcs. – plastic containers (1) – cardboard packs.
80 pcs. – plastic containers (1) – cardboard packs.
100 pcs. – plastic containers (1) – cardboard packs.
Clinical-Pharmacological Group
Enzyme preparation
Pharmacotherapeutic Group
Digestive enzyme agent
Pharmacological Action
A combined medicinal product, the action of which is determined by the components that make up its composition. It has proteolytic, amylolytic, and lipolytic action.
It promotes rapid and complete digestion of food, eliminates symptoms arising from digestive disorders (feeling of heaviness and fullness in the stomach, flatulence, feeling of lack of air, shortness of breath caused by gas accumulation in the intestines, diarrhea).
It improves the process of food digestion in children; stimulates the secretion of the body’s own enzymes of the pancreas, stomach, and small intestine, as well as bile.
Bile extract acts choleretically, promotes fat emulsification, increases lipase activity, improves the absorption of fats and fat-soluble vitamins A, E, K. Hemicellulase is an enzyme that promotes the breakdown of plant fiber.
Indications
Exocrine insufficiency of the pancreas, stomach, intestines, liver, gallbladder (chronic inflammatory-dystrophic diseases of these organs, condition after resection or irradiation); flatulence, diarrhea of non-infectious origin; cystic fibrosis.
To improve food digestion in individuals with normal gastrointestinal function in case of dietary errors (consumption of fatty foods, large amounts of food, irregular meals); in cases of chewing function impairment (damage to teeth and gums, during the period of adaptation to an artificial jaw); sedentary lifestyle; prolonged immobilization.
Preparation for X-ray examination and ultrasound of the abdominal organs. As an auxiliary medicinal product for faster absorption of certain medicines (PAS, sulfonamides, antibiotics).
ICD codes
| ICD-10 code | Indication |
| E84 | Cystic fibrosis |
| K29 | Gastritis and duodenitis |
| K30 | Functional dyspepsia (digestive disorder) |
| K52.9 | Noninfective gastroenteritis and colitis, unspecified |
| K59.1 | Functional diarrhea |
| K81.1 | Chronic cholecystitis |
| K86.1 | Other chronic pancreatitis |
| K86.8 | Other specified diseases of pancreas (atrophy, calculi, cirrhosis, fibrosis of pancreas) |
| K90.3 | Pancreatic steatorrhea |
| K91.1 | Postgastric surgery syndromes |
| K91.2 | Postprocedural malabsorption, not elsewhere classified |
| K91.5 | Postcholecystectomy syndrome |
| R14 | Flatulence and related conditions (including abdominal bloating, belching) |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| Z72.4 | Inappropriate diet and harmful eating habits |
| ICD-11 code | Indication |
| CA25.Z | Cystic fibrosis, unspecified |
| DA42.Z | Gastritis, unspecified |
| DA51.Z | Duodenitis, unspecified |
| DA7Z | Diseases of stomach or duodenum, unspecified |
| DA90.0 | Syndromic diarrhea |
| DA96.0Y | Other specified intestinal malabsorption |
| DC12.1 | Chronic cholecystitis |
| DC14.1 | Postcholecystectomy syndrome |
| DC32.0 | Calcific pancreatitis |
| DC32.1 | Paraduodenal pancreatitis |
| DC32.2 | Hereditary chronic pancreatitis |
| DC32.4 | Chronic idiopathic pancreatitis |
| DC32.5 | Tropical pancreatitis |
| DC32.Z | Chronic pancreatitis, unspecified |
| DC33 | Autoimmune pancreatitis |
| DC34 | Obstructive pancreatitis |
| DC35.2 | Pancreatic steatorrhea |
| DC35.Z | Other specified diseases of pancreas, unspecified |
| DC3Z | Diseases of pancreas, unspecified |
| DD90.0 | Globus sensation |
| DD90.1 | Functional dysphagia |
| DD90.3 | Functional dyspepsia |
| DD90.Z | Functional disorders of esophagus or gastroduodenal system, unspecified |
| DD91.2 | Functional diarrhea |
| DD93.Y | Other specified functional gastrointestinal disorders in infants, toddlers and school-age children |
| DD9Z | Functional gastrointestinal disorders, unspecified |
| DE11 | Dumping syndrome |
| DE2Z | Diseases of the digestive system, unspecified |
| ME08 | Flatulence and related conditions |
| QB9A | Preparatory procedures for subsequent treatment |
| QE23 | Problems with inappropriate nutrition or eating habits |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Orally, 1 single dose 3 times/day during or immediately after meals. Swallow whole, do not chew. If necessary, the single dose can be doubled.
The duration of treatment ranges from several days (in case of digestive disorders due to dietary errors) to several months and years (if constant replacement therapy is necessary).
Before X-ray examination and ultrasound – 2 single doses 2-3 times/day for 2-3 days before the examination.
Adverse Reactions
Allergic reactions skin hyperemia, sneezing, lacrimation.
From the digestive system diarrhea, nausea, abdominal pain (including intestinal colic). In children (when taken in high doses) – perianal irritation, irritation of the oral mucosa.
From metabolism hyperuricemia, hyperuricouria.
Contraindications
Hypersensitivity; hyperbilirubinemia; acute pancreatitis, chronic pancreatitis (exacerbation), hepatitis, hepatic insufficiency, hepatic coma or precoma, gallbladder empyema, cholelithiasis, mechanical jaundice, intestinal obstruction.
With caution cystic fibrosis, pregnancy; children’s age (under 3 years).
Use in Pregnancy and Lactation
With caution: pregnancy.
Use in Hepatic Impairment
Contraindicated in hepatitis, hepatic insufficiency, hepatic coma or precoma.
Pediatric Use
With caution: children’s age (under 3 years).
Drug Interactions
Reduces the bioavailability of iron preparations
Increases the absorption of PAS, sulfonamides, antibiotics.
Cimetidine enhances the effect of the preparation.
Antacids containing magnesium and/or calcium ions reduce the effectiveness of the preparation.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer